Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Comments
Loading...

Ratings for Personalis PSNL were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 7 0 0 0 0
Last 30D 1 0 0 0 0
1M Ago 3 0 0 0 0
2M Ago 2 0 0 0 0
3M Ago 1 0 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $8.68, a high estimate of $11.00, and a low estimate of $7.25. This upward trend is evident, with the current average reflecting a 1.64% increase from the previous average price target of $8.54.

price target chart

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of Personalis by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Swayampakula Ramakanth HC Wainwright & Co. Lowers Buy $8.00 $11.00
Thomas Flaten Lake Street Raises Buy $9.00 $7.00
Swayampakula Ramakanth HC Wainwright & Co. Maintains Buy $11.00 $11.00
Mike Matson Needham Maintains Buy $7.25 $7.25
Mike Matson Needham Maintains Buy $7.25 $7.25
Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $11.00 $9.00
Mike Matson Needham Maintains Buy $7.25 $7.25

Key Insights:

  • Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Personalis. This information offers a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Personalis compared to the broader market.
  • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Personalis's stock. This comparison reveals trends in analysts' expectations over time.

For valuable insights into Personalis's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.

Stay up to date on Personalis analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Personalis: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Personalis displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 40.89%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -152.04%, the company showcases strong profitability and effective cost control.

Return on Equity (ROE): Personalis's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -28.02%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Personalis's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -18.38%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: Personalis's debt-to-equity ratio is below the industry average. With a ratio of 0.27, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Analyst Ratings: What Are They?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!